What is Citryll?
Citryll is a specialized biotechnology enterprise dedicated to pioneering an innovative approach to treating immune-mediated inflammatory diseases. The company distinguishes itself by targeting Neutrophil Extracellular Traps (NETs), which are identified as a fundamental, yet previously unaddressed, component of the inflammatory process. By focusing on these mechanisms, Citryll aims to move beyond traditional pathway management and symptom-based treatments, effectively reducing the inflammatory drive at its source. This strategic focus positions the company at the intersection of advanced immunology and pharmaceutical development, offering a transformative potential for patients suffering from chronic inflammatory conditions. The firm's operational model leverages deep scientific expertise to translate complex biological insights into viable clinical solutions, establishing a robust market position within the life sciences sector.
How much funding has Citryll raised?
Citryll has raised a total of $127.9M across 3 funding rounds:
Series A
$17.2M
Series B
$20.8M
Series B
$89.9M
Series A (2019): $17.2M with participation from ModiQuest B.V., BOM Brabant Ventures, Curie Capital, and BrightGene
Series B (2020): $20.8M led by ModiQuest B.V., BOM Brabant Ventures, BGV (BioGeneration Ventures), BrightGene, and Seventure Partners
Series B (2024): $89.9M supported by Curie Capital, Novartis, Johnson & Johnson Innovation, and Forbion
Key Investors in Citryll
Forbion
Forbion is a global life sciences venture capital firm that sources, builds, and guides biotech and biopharmaceutical companies from early-stage development through to clinical maturity.
Novartis
Novartis is a global pharmaceutical manufacturer specializing in the research and development of innovative medications and healthcare solutions across multiple therapeutic areas.
Johnson & Johnson Innovation
Johnson & Johnson Innovation partners with entrepreneurs and early-stage businesses to develop transformational healthcare solutions through a global network of regional innovation centers.
What's next for Citryll?
With the successful completion of this major enterprise-level funding, Citryll is well-positioned to advance its clinical development pipeline and expand its research capabilities. The strategic backing from industry leaders and specialized life sciences investors provides not only the necessary capital but also the operational expertise required to navigate the complexities of drug development and regulatory approval. Moving forward, the company is expected to prioritize the validation of its NET-targeting platform in human trials, aiming to demonstrate superior efficacy over existing standards of care. As Citryll scales its operations, the focus will likely shift toward establishing further collaborative partnerships and optimizing its therapeutic candidates for broader market application, ultimately aiming to redefine the treatment paradigm for systemic inflammatory disorders.
See full Citryll company page
